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ABSTRACT 
Efforts to develop urea derivatives as anticancer agents thrive due to their proven anticancer activities. N-(4-tert-
butylphenylcarbamoyl)benzamide was synthesized by Schotten Baumann reaction, rendering 59%. To determine the 
purity, a thin-layer chromatography method in 3 different mobile phases was adopted, indicating a stain with 
distinguishing Rf. Structure identification indicating the compound was N-(4-tert-butylphenylcarbamoyl)benzamide. 
To predict cytotoxic activity, molecular docking with Autodocks Program was used by supplementing CHK1 
enzyme (code PDB: 2YWP) against HeLa cells. The prediction score was confirmed by Molecular Docking 
Simulation (MDS). N-(4-tert-butylphenylcarbamoyl)benzamide (-4.41) has a smaller docking score compared to that 
of hydroxyurea (-2.69), suggesting higher cytotoxicity. MDS score highlighting this compound with (-
13.1223±4.6818) total energy, smaller than the one in reference compound, (-0.0446±0.3621). This new compound 
indicated properties with favorable anticancer activity in the ADMET prediction, due to the toxicity displayed 
against the organ. On the cytotoxic activity test against HeLa cells, the IC50 of-(4-tert-
butylphenylcarbamoyl)benzamide is 3.78 nM, smaller than that of hydroxyurea, IC50 9.91 nM. The data suggest that 
the synthesized N-(4-tert-butylphenylcarbamoyl) benzamidedisplays higher cytotoxic activity compared to 
hydroxyurea. This synthesized compound allows further study in drug development, serving as a new anticancer 
agent. 
Keywords: Molecular Docking, Molecular Dynamic Simulation, ADMET Prediction, Synthesis, Cytotoxic 
Activity, N-(4-tert-butylphenylcarbamoyl)benzamide, HeLa Cells 
RASĀYAN J. Chem., Vol. 14, No.2, 2021 
 
INTRODUCTION 
The imbalance between the production and scavenging of Reactive Oxygen Species (ROS) results in the 
disruption of normal cell function, leading to damage on protein, DNA, tissue, and biomolecule that 
induces the growth of new cells known as cancer cells. In the future, cancers will be more and more 
diagnosed, with lung and breast cancers rank the highest. According to National Breast Cancer 
Foundation in America, approximately 200,000 women were diagnosed with breast cancer.1 
Cancer has become the second leading cause of mortality across the globe. As a result, coping with cancer 
is inevitably crucial in the field of medicine. The use of complementary and alternative drugs has become 
ubiquitous, encouraging rapid growth in drugs development, particularly in Asian countries.2 
Modern drugs have successfully become an effective treatment for malignant tumors, and they are 
continuously developing. The failing therapy on cancers is primarily due to unspecific drug compounds, 
drug resistance, and the complications of the patients. Hydroxyurea is one of the cancer drugs working to 
inhibit the mitosis process of cancer cells and thus prevent them from proliferating. The urea protein 
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structure as a pharmacophore allows other urea derivative compounds to display anticancer activity as 
well.3 
Hydroxyurea has gained popularity as an anticancer drug. Yet, its ability to penetrate biological 
membranes is uncertain. The hydroxyl group bound to one of the nitrogen atoms turns the compound to 
be hydrophilic. Changing the structure of the urea compound is to improve the compound’s penetration 
into a biological membrane. Adding a phenyl group to one of the nitrogen atoms will result in better 
penetration of this urea derivatives compound compared to hydroxyurea. The phenyl group, as in the N-
phenyl urea compound, will lead to a more lipophilic compound compared to hydroxyurea. Thus the 
compound can penetrate the biological membrane more easily.4 
Some researchers have developed N-phenylurea and its derivatives as anticancer agents. Song et al. 
(2009) has synthesized 3-haloacylamino-phenylureas. Bromoacetil group bound to one of the hydrogen 
atoms exhibit potent anticancer activity against 8 human tumor cells with IC50of 0.38 - 4.07 uM.5 Another 
study conducted by Szafranski et al. (2015) synthesized 4-substituted-N-(phenylcarbamoyl)-3-pyridine 
sulfonamide compound and its derivatives. One of the derivatives N-(4-chlorophenylcarbamoyl)-4(4-(3,4-
dichlorophenyl)piperazine-1-yl)pyridine-3-sulfonamide has potent antitumor activity against leukemia, 
colon cancer and melanoma with IC50 of 13.6-14.9 uM.6 In addition, another N-phenylurea derivative 
compound- 1-(2-methyl-6-arylpyridine-3-yl)-3-phenylurea - has been synthesized with its 51 derivatives 
having potent anticancer activities against lung cancer A549 and colon cancer HCT-116 with IC50 of 
3.22±0.2 dan 2.71±0.16 uM.7 
Predicting anticancer activity of N-phenylurea derivatives may adopt In-silico test molecular modeling 
with certain computer programs e.g. Autodock. This program allows investigating the reaction between 
the compound and the receptor or enzymes that play roles in the proliferation of cancer cells. One of these 
enzymes is Checkpoint kinase-1(CHK1) which contributes to the increasing damage of DNA on p-53 
deficient cell. This DNA damage induces the phosphorylation process which terminates cell proliferation 
on phase S and G2. Therefore, the rise in Checkpoint kinase-1(CHK1) may expand DNA damage 
selectively on cancer cells, thus the existence of a selective inhibitor compound on CHKI is applicable for 
highly favorable cancer therapy.8 The compound prepared for a synthesis underwent an activity prediction 
test for its anticancer properties, through In-silico and molecular docking process against CHK-1 enzyme 
to obtain Molecular Docking Score (MDS) which would be compared with the standard compound, 
hydroxyurea.8 The ADMET prediction process was also required due to the novelty of N-(4-tert-
butylphenylcarbamoyl)benzamidecompound to properly investigate the prediction score of absorption, 
distribution, metabolism, excretion and also the toxicity. This enables further development of the 
compound as a novel anti-cancer agent.9 
N-(4-tert-butylphenylcarbamoyl)benzamide, the synthesized N-phenylurea derivative compound, was 
derived from nucleophilic acylation between N-phenylurea and 4-tert-butylbenzoyl chloride using 
Schotten Baumann method.10 The physical and chemical properties of the synthesized compound changed 
in the process. The lipophilic, electronic and steric properties turned higher compared to the original 
compound, thus enhancing the anticancer activity of the synthesized compound.4 
By applying the MTT assay method and using HeLa cancer cells - standard cells most commonly used in 




Materials for physicochemical synthesis and analysis: N-phenylurea, 4-t-butylbenzoyl chloride, pyridine, 
variants of organic solvent (acetone, ethyl acetate, n-hexane, chloroform, ethanol, and methanol with pro 
analysis quality), Kieselgel 60 F254, DMSO-d6.  
Materials for activity test: Synthesized compound, HeLa culture cell, Culture Media DMEM. DMSO, 
Phosphate-buffered Saline (PBS), MTT [3-(4,5-dimethylthiazol-2-il)-2,5-diphenyltetrazolium bromide], 
SDS 10% in 0,1 N HCl.Standard compound: hydroxyurea (Sigma Aldrich). 
 
The Tools used for Synthesis and Analysis of Compound Structure 
Glass tube, UV-vis Shimadzu HP 8452 ASpectrophotometer, Jasco FT-IR 5300 Spectrophotometer, NMR 
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Hitachi R-1900Spectrometer, Electrothermal Mel-Temp, Corning Hot Plate P 351, Shimadzu LM-20 
analytical balance.  
 
Tools for Cytotoxic Test 
Micropippet 200, 1000 μL and tip, culture tube, microplate, Conical tube, ELISA-Reader. 
 
Devices and Software used for Molecular Modelling  
Lenovo computer, operating system Windows 10, 64 bit, intel core i-5-7200 U, CPU@250 GHz, 8.00 GB 
RAM. Mgl Tools (Version 1.5.6). AutoDockTools (Version 4.2.6) with Autogrid. 
 
Devices used for ADMET Prediction 
Lenovo computer, operating system Windows 10, 64 bit, intel core i-5-7200 U, CPU@250 GHz, 8.00 GB 
RAM. Chem.Bio.Draw Ultra Version 12 (Cambridge Soft); Chem.Bio3D Ultra Version 12 (Cambridge 
Soft); Online SMILES Translator, and pkCSM online tool. 
 
Docking Method Validation 
When doing docking protocol on N-(4-tert-butylphenylcarbamoyl)benzamidecompound using Autodock 
4.2.6 dan Autogrid program, it is required to perform method validation by redocking its native ligand to 
A41_1 protein, whose native ligand has been removed. The parameter for this method validation is the 
value of Root Mean Square Deviation (RMSD), with a tolerable value of ≤ 2.0 Ao.12 
 
In-silico Prediction on Cytotoxic Activity 
Autodocks software (Version 4.2.6) was used to predict the cytotoxic activity of this compound. 
Molecular docking simulation is performed between the test compound and checkpoint kinase1 enzyme 
(CHK1), ID PDB: 2YWP which contains a ligand of 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-
cyanopyrazin-2-yl)urea (A42_1), downloaded from Protein Data Bank (PDB) server. 
To prepare protein and ligand molecule, Mgl Tools (Version 1.5.6) was used. And to obtain a 
perfect/great assignment grid parameter of each ligand, the grid box was generated by trials and errors.  
The grid box dimension of X: 32, Y: 20, Z: 16, while the grid box center of X: -3.864, Y: 9.389, Z: -
18.202 were used for docking calculation. Subsequently, the docking process was conducted by running 
the Lamarckian Genetic Algorithm. Here, the default parameters and one hundred independent docking 
runs were carried out for every chemical structure.13-17 
 
Molecular Dynamics Simulation 
The ligand-receptor binding energy that has been calculated using molecular docking procedure should 
allow validations on molecular dynamics simulation.18 This simulation procedure adopts the Amber 
Molecular Dynamics program package for 10ns simulation.19 The trajectory files from this simulation 
were analyzed to calculate free energy binding between receptors and each of the ligands.    To calculate 
the simulation, Python interpreter module and MMPBSA.py in Amber Molecular Dynamics Package 
Program were employed. Before calculating, the complex bindings between the receptor of checkpoint 
kinase1 and the native ligand model (PDB ID: 2YWP) were downloaded from the PDB server. This 
process worked with the UCSF Chimera program.20 Partial atomic charges were added to each 
standardized residual of the receptor using Molecular Mechanics (MM) software with AMBER ff14SB 
force field. While for non-standardized residuals of the ligand, the semi-empirical AM1-BCC method was 
applied.21 Other ligands in this experiment - 4TBPCB, and HU were converted from their 2D to 3D 
ligands using the semi-empirical PM6 method.   
 
ADMET Prediction 
The prediction on pharmacokinetic properties (ADMET: Absorption, Distribution, Metabolism, Excretion 
and Toxicity) of the active compound was determined using pkCSM online tool software. The 2D 
structure of the active compound was illustrated in Chem. Bio. Draw. Ultra-Version 12.0 programe. To 
obtain the 3D image of the structure, the illustration was copied to Chem. Bio. 3D Ultra Version 12.0 
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software and saved on *.sdf files and subsequently interpreting the active compound data on SMILE 
format in Online SMILES translator (http://cactus.nci.nih.gov/translate/). In its SMILES format, the 
active compound underwent ADMET prediction by utilizing pkCSM online tool 
(htpp://biosig.unimelb.edu.au/pkCSM/prediction).22,23 
 
Synthesis of-(4-tertier-butylphenylcarbamoyl) benzamide Compound 
0,03 mol of N-phenylurea compound was mixed with 40 ml of tetrahydrofuran and pyridine4 ml on a 200 
in a round-bottom flask. 4-t-butylbenzoyl chloride 0,01 mol was added at 5ºC temperature into 20 ml of 
tetrahydrofuran and placed on a magnetic stirrer hotplate. Once 4-t-butylbenzoyl chloride solution was 
completely heated up, the mixture was refluxed and stirred for 8 hours.  
Upon terminating the reaction, tetrahydrofuran was then evaporated on rotavapor. Saturated natrium 
bicarbonate liquid was supplemented on the reaction outcome and stirred to eliminate any bubbles. Using 
Buchner filter funnel, the solid substance was rinsed with 50 ml water and repeated twice, followed by a 
wash with 10 ml ethanol two times. The recrystallization process was performed by diluting the solid 
substance with hot ethanol adequately while stirred in a hot plate. The solution was filtered while hot and 
stored at room temperature overnight. The crystallized substance was filtered with a Buchner funnel, 
washed in 10 ml ethanol twice. Recrystallization can also be conducted using another appropriate solution 
depending on the synthesized compound, like acetone-water. The crystal formed was transferred to a petri 
dish, dried in a 50ºC oven to obtain a constant mass.24-27 
The structure identification of active N-(4-tert-butylphenylcarbamoyl)benzamide  utilized the following 
instruments: UV-Vis dan IR spectrophotometer, 1H-NMR, dan Mass spectrometer.28 





Fig.-2: The Synthesis Reaction of N-(4-tert-butylphenylcarbamoyl)benzamide 
 
Cytotoxic Activity Test 
Anticancer activity or cytotoxic test in vitro with cancer cells were proceeded with MTT assay approach. 
A mother compound was prepared from the test compound, N-(4-tert-butylphenylcarbamoyl)benzamide, 
as much as 5000 μg/mL in DMSO solution. From each mother compound, a series of standard 
compounds with 250, 500, 750, 1000, 1500, 2000 μg/mL concentrations were prepared by dilution. As a 
positive control, standard anticancer drug solution, hydroxyurea was prepared along with solvent blanks 
as a negative control.  
The culture of cancer cells (HELA cells) was prepared, and so with normal cells in cell suspension with 
105-2.106. density. Each 100 L of the cells were seeded in Microplate wells, except those for control 
media. 0,2 mL of standard solution, positive and negative control, each was added in a microplate well. 
Each standard solution was replicated 3 times. The microplate was incubated for 24 hours in 5% CO2 
incubator at 37ºC with pH 7.4-7.7.  
MTT reagent was prepared for 0,5 mg/ml treatment by diluting 1mL of MTT stock (there is 50 mg MTT 
in 10 mL PBS) with adequate media. After incubation, cell media was removed, and cells were washed in 
PBS then added with 100 μL of MTT reagent on each well, including control media (no cells included). 
The plate was incubated for 24 hours. Once formazan was formed, it was added with 100μL SDS 10% in 
0,1 N HCl. The plate was covered with aluminium paper and incubated in a dark room at room 
temperature for 24 hours. The absorbance of each well was examined in an ELISA reader at 595 nm 
N-Phenylurea (a) 4-t-Butylbenzoyl chloride (b) N-(4-tert-
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wavelength. The more cells proliferate, the bigger is the absorbance. The IC50 of the test compound was 
determined with probit regression analysis.29 
 
RESULTS AND DISCUSSION 
Docking Validation Score 
After performing the validation method by the redocking native ligand on A42_1 protein, whose native 
ligand has been removed, Root Mean Square Deviation (RMSD) value was obtained: 1.02 Ao. The 
tolerable RMSD value is ≤ 2.0 Ao. 
In this study, as indicated in Table-1, the average value of RMSD of a native ligand with A42_1 is 1.02. 
This means Autodock 4.2 and Autogrid method have met the requirements for validation. 
 
In-silico Molecular Modeling  
The result of molecular docking of standard ligand compound 1-(5-Chloro-2,4- dimethoxy-phenyl) -3-(5-
cyanopyrazin-2-yl)urea, reference compound Hydroxyurea and test compound N-(4-tert-
butylphenylcarbamoyl)benzamideusing Autodock 4.2.6 program can be seen in Table-1. 
 
Table-1: Molecular Docking Score on Standard Ligand Compound, Hydroxyurea and N-(4-tert-
butylphenylcarbamoyl)benzamide using Autodock 4.2.6 Program 
 
Compound MDS Interactions of Ligand-amino acid 
1-(5-Chloro-2,4-dimethoxyphenyl)-
3-(5-cyanopyrazin-2-yl)urea 
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Interactions between ligand molecules and receptors were as displayed in Table-1. N-(4-tert-
butylphenylcarbamoyl)benzamide compound demonstrate docking score of -4.41, smaller compared to 
that of hydroxyurea, -2.69. This indicates that the binding between N-(4-tert-
butylphenylcarbamoyl)benzamidewith its receptor is substantially more stable due to the smaller energy 
required. In addition, there are a lot more bindings between N-(4-t-butylphenylcarbamoyl)benzamide 
compound and amino acid proteins ( CysA:87; LysA:38; GlyA:16; ValA:58; LeuA:84; AspA:148; 
SerA:147; Val A:23; LeuA:137; Leu A:15; GluA:91) compared to those with hydroxyurea (ValA:23; 
LeuA:15; Tyr A:86; GluA:85; Ala A:36; CysA:87; LeuA;137). Thus, the binding between N-(4-t-butyl-
phenylcarbamoyl)benzamide with the receptors will be stronger. Therefore, it is predicted that N-(4-tert-
butylphenylcarbamoyl)benzamidehas higher cytotoxic activity than that of hydroxyurea. However, when 
compared to the native ligand, A42_1, N-(4-tert-butylphenylcarbamoyl)benzamidehas a greater MDS  
value. Hence, it is predicted that this compound has less cytotoxic activity.  
 
Molecular Dynamics Simulation  
Binding free energy calculated from this simulation for hydroxyurea (HU) and N-(4-tert-
butylphenylcarbamoyl)benzamide (4TBPCB) was listed in Table-2. 
 




VDWAALS -14.8863 ± 5.0141 -0.0931 ± 0.4101 
EGB 3.7761 ± 1.1997 0.0675 ± 0.1999 
ESURF -2.0121 ± 0.6470 -0.0190 ± 0.1092 
DELTA G gas -14.8863 ± 5.0141 -0.0931 ± 0.4101 
DELTA G solv 1.7641 ± 0.7831 0.0485 ± 0.1223 
DELTA Total -13.1223 ± 4.6818 -0.0446± 0.3621 
 
To substantiate the prediction of cytotoxic activity of N-(4-tert-
butylphenylcarbamoyl)benzamidecompound, Molecular Dynamic Simulation (MDS) was performed as 
displayed in table 2. N-(4-tert-butylphenylcarbamoyl)benzamide has a component total energy of -
13.1223, far smaller compared to that of hydroxyurea, -0.0446. This confirms the prediction that the 
cytotoxic activity of N-(4-tert-butylphenylcarbamoyl) benzamide is higher than that of hydroxyurea. 
 
ADMET Prediction 
ADMET prediction score of reference compound hydroxyurea (HU) and test compound N-(4-tert-
butylphenylcarbamoyl)benzamide (4TBPCB) can be seen in Table-3. 
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Table-3: ADMET Prediction of Reference Compound hydroxi urea (HU) and Test Compound N-(4-tert-
butylphenylcarbamoyl)benzamide(4TBPCB) 
 
As many as 2.245 drug compounds were analyzed by Lipinski et al., and listed in World Drug Index and 
known as Lipinski rule of 5 since the resulted analysis values are multiples of Five. When a drug 
compound has a molecular weight > 500, it will be difficult to be absorbed with low permeability. The 
Partition Coefficient Log value on octanol/water (logP) is bigger than +5, hydrogen binding donor value 
(HBond=HBD) was expressed by the number of bindings of OH and NH groups, more than 5, and 
Hydrogen receptor (HBO) expressed by the number of O and N atoms, more than 10.30. 
N-(4-tert-butylphenylcarbamoyl)benzamidecompound has a molecular weight of 296.36, smaller than 
500, with Partition Coefficient Log value on octanol/water (logP) = 4.16, smaller than +5. The number of 
OH and NH groups = 2, less than 5, while the number of O and N atoms = 4, less than 10. Hence, this 
compound is predicted to have great absorption and high permeability.    
After administering oral medication, drugs are normally best absorbed in the intestine. Here, the number 
of absorbed compounds can be predicted. When less than 30%, it means the absorption is poor.30 Ideally, 
drug compounds have 90% of oral bioavailability with no individual variability.31 In Table-3, N-(4-tert-
butylphenylcarbamoyl)benzamideseems to have human intestinal absorption of 90.931%, meaning that 
the compound is predicted to have good bioavailability. 
For transdermal drug development, skin permeability is compelling to study. Skin permeability 
coefficient is stated with Kp (cm/h) log value that allows skin permeability prediction on drug compound. 
One compound is predicted to have skin permeability when the Kp (cm/h) log value Kp > -2.5. In Table-
3, N-(4-t-butyl-phenylcarbamoyl) benzamide compound has log value of Kp -3.08 (cm/h), which means 
that this compound has low permiability.32 
The volume of distribution (VDss) is the theoretical volume of drugs total dosage required for 
distribution, thus enables equal concentration in blood. When a compound is high in VDss value, it can be 
said that the compound is distributed more in the tissue than in blood plasma. When the log value is VDss 
< -0.15, it suggests a low distribution. When the log value is VDss > 0.45 then it has high distribution.32 
In table 3, N-(4-tert-butylphenylcarbamoyl)benzamidecompound is shown to have log value VDss -0.238, 
meaning that this compound has a low distribution volume. 
According to Pires et al (2015), a compound is considered capable of penetrating the blood-brain barrier 
well when it has Log BB > 0,3. On the other hand, with log BB < -1 a compound is unable to distribute 
well. In Table-3, N-(4-tert-butyl-phenylcarbamoyl)benzamide compound indicates a value of log BB 
0.365. Thus, it can be inferred that this compound is incapable of penetrating the blood-brain barrier.32 
Cytochrome P450 is an important enzyme in the detoxification process and is the primary enzyme located 
in the liver. This enzyme plays a significant role in the oxidation process and may facilitate excretions of 
foreign organic compounds including drugs. It is crucial to note that drug compounds may inhibit the 
cytochrome P450 enzyme from functioning. In this study, it is represented by Cytochrome P3D6 isofarm 
(CYP2D6). N-(4-tert-butylphenylcarbamoyl)benzamidecompound in Table-3 indicates that it does not 
inhibit the function of the cytochrome P450 enzyme.  
The excretion process of drug compounds is possible to predict by measuring the total clearance (Cltot) 
and Renal Organic Cation Transporter 2 (OCT2) substrate. C1 total is a combination of hepatic clearance 
ADMET Test HU 4TBPCB 
Absorption 
Intestinal Absorption (human) in % 




















Renal OCT2 Substrate 
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(metabolism in liver and bile) and renal excretion. In table 3, N-(4-tert-butylphenylcarbamoyl)benzamide 
compound has a value of 0.234 which indicates the excretion speed of the compound.  
OCT2 is a transporter in the kidney that has an important role in the disposition and clearance of drug 
compounds and endogen compounds in the human body. N-(4-tert-
butylphenylcarbamoyl)benzamidecompound in Table-3 demonstrates that this compound does not affect 
OCT 2, enabling the compound to excreted so easily.32 
Ames cytotoxic test is an assay to demonstrate the toxicity of a compound and is commonly adopted to 
access the mutagenic nature of a compound using bacteria. When tested positive, it suggests that the 
compound is mutagenic dan possibly act as a carcinogen. N-(4-tert-butylphenylcarbamoyl)benzamidein 
Table-3 displays that this compound is nontoxic both in Ames test and hepatotoxicity. Hence, this 
compound is considered safe. In a compound with LD50 test on mice, the value is 1.611 mg/kgBW, 
suggesting that the compound has a low toxicity value. To kill a guinea pig 50%, it takes 457mg/kgBW 
dosage. 32 
 
Chemical Structure Identification 
N-(4-tertier-butylphenylcarbamoyl)benzamide, yield: 59%; MP: 171oC; UV (methanol, λmaks, nm): 236;  
FT-IR (KBr pellet, cm-1): 3467 (NH sec), 2965 (C-H alkane), 1685 and 1610 (2 C=O ureide), 1568, 1423 
(C=C arom); 1-H-NMR (DMSO-d6, σ, ppm): 7.00-8.20 (m, 9H, C6H5 and C6H4); 10.20 (s, 1H, NH); 10.80 
(s, 1H, NH); 1.0-1.6 (m, 9H, C(CH3)3; MS (EI; m/e): 246 (M)+. 
According to the interpretation data of compound structure in item 4, where there are 2 carbonyl ureida 
groups on wave number 1685 and 1610 cm-1 on Infra-Red interpretation. This is then confirmed with 9 
hydrogen atoms on 7.00-8.20 ppm chemical shifton 1H-NMR spectrum. In addition, a molecular weight 
of the compound interpreted on Mass Spectral Method (246) shows that N-(4-tert-
butylphenylcarbamoyl)benzamidecompound has been successfully synthesized and has structures as 











Fig.-5: Structure of N-(4-tert-butylphenylcarbamoyl)benzamide 
 
Cytotoxicity Test with HeLa Cells 
Data of cytotoxicity test with HeLa cells from reference compound Hydroxyurea and test compound N-
(4-tert-butylphenylcarbamoyl)benzamide are shown in Figs.-3 and 4 and Table-4. 
 
Fig.-3: Cytotoxic Activity Curve of N-(4-tert-butylphenylcarbamoyl)benzamide Compound 
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Fig.-4: Cytotoxic Activity Curve of Hydroxyurea 






Hydroxy Urea 4TBPCB 
250 84.79 76.15 
500 83.21 71.02 
750 80.51 52.29 
1000 77.61 49.16 
1500 76.21 39.53 
2000 76.15 35.14 
 
According to the data shown in table 3 for N-(4-tert-butylphenylcarbamoyl)benzamide compound and 
hydroxyurea, curve image on figure 2 and curve image on figure 3, it can be seen that N-(4-tert-
butylphenylcarbamoyl)benzamide compound has higher cytotoxic activity compared to hydroxyurea. On 
a conducted regression analysis, the IC50 of N-(4-tert-butylphenylcarbamoyl)benzamide compound 
obtained is 9.1 mM. It can be inferred that N-(4-tert-butylphenylcarbamoyl)benzamide compound has far 
greater cytotoxicity compared to hydroxyurea. 
 
CONCLUSION 
N-(4-tert-butylphenylcarbamoyl)benzamide compound has been synthesized and has a great cytotoxic 
activity, allowing further study in drug development and serves as a new anticancer agent. 
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